BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhu X, Li Q, Song W, Peng X, Zhao R. P2X7 receptor: a critical regulator and potential target for breast cancer. J Mol Med (Berl) 2021;99:349-58. [PMID: 33486566 DOI: 10.1007/s00109-021-02041-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Le Naour J, Sztupinszki Z, Carbonnier V, Casiraghi O, Marty V, Galluzzi L, Szallasi Z, Kroemer G, Vacchelli E. A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients. OncoImmunology 2022;11:2059878. [DOI: 10.1080/2162402x.2022.2059878] [Reference Citation Analysis]
2 Ferrari D, Gessi S, Merighi S, Nigro M, Travagli A, Burns JS. Potentiating Cancer Immune Therapy via Nanomaterials and Purinergic Signaling. Front Cell Dev Biol 2022;10:893709. [DOI: 10.3389/fcell.2022.893709] [Reference Citation Analysis]
3 Salahuddin MM, Omran GA, Helmy MW, Houssen ME. Effect of Regorafenib on P2X7 Receptor Expression and Different Oncogenic Signaling Pathways in a Human Breast Cancer Cell Line: A Potential of New Insight of the Antitumor Effects of Regorafenib. Curr Issues Mol Biol 2021;43:2199-209. [PMID: 34940128 DOI: 10.3390/cimb43030154] [Reference Citation Analysis]
4 Canales Coutiño B, Mayor R. Mechanosensitive ion channels in cell migration. Cells Dev 2021;166:203683. [PMID: 33994356 DOI: 10.1016/j.cdev.2021.203683] [Reference Citation Analysis]
5 Kim R, Kin T. Current and Future Therapies for Immunogenic Cell Death and Related Molecules to Potentially Cure Primary Breast Cancer. Cancers (Basel) 2021;13:4756. [PMID: 34638242 DOI: 10.3390/cancers13194756] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]